
The dosage of Danazol is the key to the correct use of the drug, and patients should consult their doctor or pharmacist carefully before using Danazol to ensure that they understand the use and dosage of the drug.
What is the dosage of Danocrine?
Danazol is a drug clinically used for the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema, and has a certain effect in clinical treatment.
Endometriosis
For patients with moderate to severe disease or infertility with endometriosis, a recommended starting dose of 800 mg is given in two divided doses, with amenorrhea and a rapid response to painful symptoms to achieve optimal results at this dose level.
Depending on the patient's response, doctors may consider tapering the dose to a dose sufficient to maintain amenorrhea. For patients with mild disease, an initial daily dose of 200mg to 400mg is recommended to be given in two divided doses, which can be adjusted by doctors according to the patient's response.
Treatment should be started during menstruation, and if the patient is not menstruating, appropriate tests should be performed to ensure that the patient is not pregnant at the time of treatment with Danazol. Treatment with Danazol must be continued for 3-6 months and can be extended to 9 months if necessary. After treatment ends, treatment can be restarted if the patient's symptoms recur.
Fibrocystic breast disease
The total daily dose of Danazol for the treatment of fibrocystic breast disease ranges from 100mg to 400mg, administered in two divided doses depending on the patient's response. Treatment should be started during menstruation, and if the patient is not menstruating, appropriate tests should be performed to ensure that the patient is not pregnant at the time of treatment with Danazol. Because ovulation may not be suppressed, patients are advised to use non-hormonal contraceptive methods when Danazol is taken at this dose.
In most cases, breast pain and tenderness are significantly relieved in the first month and disappear after 2 to 3 months. Elimination of nodular nature usually requires 4 to 6 months of uninterrupted treatment.
About one-third of patients treated with Danazol 100 mg experience menstrual regularity, menstrual irregularities and amenorrhea, and the higher the dose, the more frequent menstrual irregularities and amenorrhea. Clinical studies have shown that 50% of patients may show signs of symptom recurrence within a year, in which case patients can resume treatment.
Hereditary angioedema
The dosing requirements for the ongoing treatment of hereditary angioedema with Danazol should be individualized based on the patient's clinical response. Patients are advised to start taking 200mg 2-3 times a day. After a good initial response to the prevention of edema episodes, the appropriate sustained dose should be determined by reducing the dose by 50% or less every 1 to 3 months or more if the pre-treatment episode frequency requires it. In case of seizures, the daily dose can be increased by up to 200 mg. During the dose adjustment phase, clinicians should closely monitor the patient's response, particularly those with a history of airway involvement.
When patients use Danazol for treatment, please follow the doctor's instructions, strictly follow the doctor's guidance for medication, and do not change the dosage or adjust the treatment plan by yourself.